News | July 06, 2012

Award supports R&D collaboration with Israel-based Check-Cap to develop 3-D imaging capsule for colorectal cancer screening

July 6, 2012 — Lantheus Medical Imaging Inc. announced the company has been selected to receive a $300,000 Massachusetts-Israel Innovation Partnership (MIIP) grant. MIIP is a formal collaboration between the state of Israel and commonwealth of Massachusetts, focused on encouraging and supporting innovation and entrepreneurship between Massachusetts’ and Israel’s life sciences, clean energy and technology sectors. The grant is made possible by Mass. Gov. Deval Patrick, Israel’s chief scientist Avi Hasson, the U.S.-Israel Science and Technology Foundation (USISTF) and the Massachusetts Technology Collaborative.

Lantheus will receive the grant upon signing a collaboration agreement with Check-Cap LTD, a medical device company, to develop and manufacture a novel, noninvasive 3-D imaging capsule to screen for polyps and lesions associated with colorectal cancer. Check-Cap LTD, which is based in Mount Carmel, Israel, is being awarded a grant from the Office of the Chief Scientist in Israel. Colorectal cancer is the second leading cause of cancer death in the United States and accounts for eight percent of cancer deaths worldwide. Early detection of polyps dramatically increases the chance for survival; however it is estimated that only half of people over the age of 50, for whom screening is recommended, currently undergo routine colonoscopies.

“We are pleased to have been selected to receive this important new grant that enables us to collaborate with Check-Cap on an innovative imaging product that can potentially change the way colon cancer is detected,” said Don Kiepert, president and CEO, Lantheus Medical Imaging. “As a global leader in diagnostic imaging, Lantheus is dedicated to providing physicians with breakthrough tools to enhance patient care. Teaming up with Check-Cap to develop and manufacture a cutting-edge imaging capsule further advances this ongoing commitment.”

“With their rich heritage in pioneering innovative imaging solutions to improve the detection of human disease, Lantheus is an ideal partner for this exciting initiative,” said Guy Neev, CEO, Check-Cap. “Despite being 90 percent curable with early detection, colon cancer remains the second-most deadly cancer in the Western world. Our unique imaging capsule may increase colorectal screening compliance without compromising screening accuracy, and has the potential to reduce the high patient mortality associated with this disease.”

For more information: www.lantheus.com


Related Content

News | Colonoscopy Systems

A team of Johns Hopkins data researchers is studying the economic and safety implications associated with the devices used to perform colonoscopies as a disposable version inches closer to widespread availability.

Time August 26, 2019
arrow
News | Colonoscopy Systems

A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection. The study is published early online in the Journal of Medical Screening.

Time August 06, 2019
arrow
News | Colonoscopy Systems

Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.

Time April 15, 2019
arrow
News | Colonoscopy Systems

https://www.congress.gov/bill/115th-congress/house-bill/1298?q=%7B%22se… cancer care advocacy groups and medical societies are calling on Congress to pass the CT Colonography Screening for Colorectal Cancer Act (S.3465/HR 1298). The bipartisan bill introduced in the U.S. Senate September 19 would provide Medicare coverage for screening computed tomography colonography (CTC), commonly known as virtual colonoscopy.

Time September 27, 2018
arrow
News | Colonoscopy Systems

Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an ingestible, capsule-based device for preparation-free colorectal cancer (CRC) screening. The company said data from the multicenter clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon.

Time September 04, 2018
arrow
News | Colonoscopy Systems

An updated American Cancer Society guideline says colorectal cancer screening should begin at age 45 for people at average risk. The recommendation is based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations.

Time May 30, 2018
arrow
News | Colonoscopy Systems

February 8, 2018 – The U.S. Food and Drug Administration (FDA) announced on February 7, 2018, that Pentax Medical’s ...

Time February 08, 2018
arrow
News | Colonoscopy Systems

August 31, 2017 — A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper ...

Time August 31, 2017
arrow
News | Colonoscopy Systems

People with insurance policies that cover computed tomography (CT) colonography for colorectal cancer screening are almost 50 percent more likely to get screened than those whose policies don’t cover the procedure, according to a new study appearing online in the journal Radiology.

Time July 12, 2017
arrow
Feature | Computed Tomography (CT) | By Jeff Zagoudis

Computed tomography colonography (CTC), also known as virtual colonoscopy, offers a noninvasive alternative to traditional (optical) colonoscopy for detection of precancerous polyps. The technology has been around for over 20 years, and numerous studies have shown it to be effective for diagnosis and screening. Questions about its utility as a screening tool persist, however, as the Centers for Medicare and Medicaid Services (CMS) reiterated in December that it will not reimburse providers for CTC in that role. The radiology community is working to change that by finding ways to improve the procedure and educating patients and providers.

Time July 05, 2017
arrow
Subscribe Now